The disclosure lawsuits are routine in M&A and unlikely to block the deal given the board's recommendation and the absence of a financing condition. Monitor for any preliminary injunction ruling before the November 16 expiration.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 13 $36.46entry
- T+1 · 20h ago +0.05%α +1.97% · $36.48
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outExecutive Summary
Viatris and its wholly owned subsidiary Peach Purchaser Sub Inc. filed Amendment No. 1 to their Schedule TO, updating the litigation section to disclose two stockholder lawsuits and fifteen demand letters challenging the adequacy of disclosures in the $36.50 per share cash tender offer for Pacira BioSciences. The Pacira defendants intend to vigorously defend the actions, and the offer terms remain unchanged.
Key Financial Metrics
Key Facts
- Two stockholder complaints filed in New York Supreme Court alleging omitted/misrepresented information in Schedule 14D-9.
- Fifteen demand letters (including two draft complaints) received by Pacira seeking additional disclosures.
- Offer price remains $36.50 per share in cash, unchanged.
- Pacira defendants intend to vigorously defend the actions.
- Tender offer expires November 16, 2026; expected close on or around November 17, 2026 per prior filings.
Financial Impact
No financial impact stated; litigation seeks injunctive relief and rescission but no damages quantified.
Risk Factors
- A court could grant preliminary injunctive relief delaying the tender offer or merger.
- Additional shareholder lawsuits or demand letters may be filed.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC TO-T/A Filing (Primary) | 0001140361-26-043435 |
| Document: 0001140361-26-043435-index-headers.html | 0001140361-26-043435 |
| Document: 0001140361-26-043435-index.html | 0001140361-26-043435 |
| Document: 0001140361-26-043435.txt | 0001140361-26-043435 |
Track record
29 reports on PCRX
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.26% at T+60 after the Aug 6, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Viewing Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers